AgingResearch.NewsJoin free

Shenzhen Oculgen Biomedical Technology

CompanyChina

Shenzhen Oculgen Biomedical Technology develops one asset, in phase 2 (OCUL101 in neovascular age-related macular degeneration). Mostly protein or enzyme; based in China.

1
Asset
Furthest stage
Phase 2
1
Trial
0
Signals

Pipeline

1

  • OCUL101

    Bispecific trap molecule simultaneously binding and inhibiting VEGF-A and complement C5.

    Phase 2, Protein or enzyme, neovascular age-related macular degeneration

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Trials1
  • Signals1
  • Similar companies6

Intelligence